A5083396561- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Neuroendocrine Tumor Research Advances
- Gastrointestinal Tumor Research and Treatment
- Angiogenesis and VEGF in Cancer
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Neuroblastoma Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Glycosylation and Glycoproteins Research
- Colorectal Cancer Surgical Treatments
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Colorectal and Anal Carcinomas
- Metastasis and carcinoma case studies
- Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Ovarian cancer diagnosis and treatment
Groupe Hospitalier Diaconesses Croix Saint-Simon
2020-2025
Pôle de Recherche pour l'Organisation et la Diffusion de l'Information Géographique
2024
British Heart Foundation
2022
University of Leeds
2022
Centre Hospitalier Saint-Joseph Saint-Luc
2016-2020
Pitié-Salpêtrière Hospital
2015-2020
Sorbonne Université
2014-2020
Assistance Publique – Hôpitaux de Paris
2012-2020
Université de Reims Champagne-Ardenne
2020
Centre Hospitalier Universitaire de Reims
2020
Multitarget antiangiogenic tyrosine kinase inhibitors (TKI) have been shown to reduce regulatory T cells (Treg) in tumor-bearing animals and patients with metastatic renal carcinomas. However, a direct role of the VEGF-A/VEGFR pathway inhibition this phenomenon is matter debate molecular mechanisms leading Treg modulation setting not explored date. proportion, number, proliferation were analyzed by flow cytometry peripheral blood colorectal cancer (mCRC) treated bevacizumab, monoclonal...
Angiography has limited value for identifying the causes of stent thrombosis (ST). We studied a large cohort patients by optical coherence tomography (OCT) to explore ST characteristics and mechanisms.A prospective multicentre registry was screened with confirmed ST. Optical performed after initial intervention culprit lesion (in 69% cases in deferred procedure). Stent classified as acute (AST), sub-acute (SAST), late (LST), very (VLST). records were analysed central core lab. The analysis...
Abstract Purpose: Despite recent therapeutic advances, prognosis of patients with pancreatic adenocarcinoma remains poor. Analyses from tumor tissues present limitations; identification informative marker blood might be a promising alternative. The aim this study was to assess the feasibility and prognostic value circulating DNA (ctDNA) in adenocarcinoma. Experimental Design: From 2011 2015, samples were prospectively collected all consecutive treated our center. Identification ctDNA done...
There is currently no standard second-line treatment for metastatic pancreatic adenocarcinoma (MPA), and progression-free survival consistently <4 months in this setting. The aim of study was to evaluate the efficacy tolerability Nab-paclitaxel plus gemcitabine (A+G) after Folfirinox failure MPA. From February 2013 July 2014, all consecutive patients treated with A+G histologically proven MPA were prospectively enrolled 12 French centres. delivered as described MPACT trial, until disease...
Abstract Background The primary objective was to evaluate the rates of older patients with colorectal cancer (CRC) who were eligible for a clinical trial, invited participate, and, ultimately, included. secondary assess reasons ineligibility, noninvitation, and noninclusion factors associated. Materials Methods Sujets AGés dans les Essais Cliniques (SAGE; Older Subjects in Clinical Trials) multicenter prospective cohort established seven centers (10 departments medical oncology, digestive...
Blockade of the human epidermal growth factor receptor 3 (HER3) and downstream phosphatidylinositide 3-kinase (PI3K)/AKT pathway is a prerequisite for overcoming drug resistance to develop novel treatments cancers that are not eligible currently approved targeted therapies. To this end, we generated specific antibodies (Abs) against domain 1 (D1) (D3) HER3 recognize epitopes do overlap with neuregulin-binding site. The fully H4B-121 Ab mouse monoclonal Abs 16D3-C1 9F7-F11 inhibited tumor in...
// Juliette Palle 1 , David Tougeron 2 Astrid Pozet 3 Emilie Soularue 4 Pascal Artru 5 Florence Leroy 6 Olivier Dubreuil 7 Matthieu Sarabi 8 Nicolas Williet 9 Sylvain Manfredi 10 Jerome Martin-Babau 11 Christine Rebischung 12 Meher Ben Abdelghani 13 Ludovic Evesque 14 Johann Dreanic 15 Vincent Hautefeuille 16 Samy Louafi 17 Sefrioui 18 Francesco Savinelli 19 May Mabro 20 Benoit Rousseau 21 Cédric Lecaille 22 Bouché 23 Christophe Louvet 24 Thierry Lecomte 25 Franck Bonnetain Julien Taieb 1,...
BackgroundImmune checkpoint inhibitors (ICI) targeting Programmed death-1 (PD-1) have shown their efficacy in advanced MSI/dMMR (microsatellite instability/deficient mismatch repair) tumors. The status predicts clinical response to ICI. promising results evaluating ICI localized tumors neoadjuvant setting need be confirmed solid aim of the IMHOTEP trial is assess anti-PD-1 treatment regarding pathological complete rate.MethodsThis study a prospective, multicenter, phase II including 120...
Triplet chemotherapy, with docetaxel-5FU-oxaliplatin (TEFOX), has yielded promising results in patients advanced and operable gastric adenocarcinoma. This may prove useful treating signet ring cell carcinoma (SRCC), which is known to be chemoresistant a poor prognosis. We therefore evaluated TEFOX untreated SRCC.Patients metastatic or locally non-resectable SRCC were treated TEFOX. Chemotherapy was administered every 14 days, combined docetaxel (50 mg/m2) oxaliplatin (85 followed by 5FU...
// Christophe Le Clorennec 1, 2, 3, 4 , Yassamine Lazrek 4, 5, 8 Olivier Dubreuil 9 Christel Larbouret Marie-Alix Poul Philippe Mondon 10 Gerry Melino 6, 7 André Pèlegrin Thierry Chardès 1 IRCM, Institut de Recherche en Cancérologie Montpellier, F-34298, France 2 INSERM, U1194 3 Université ICM, Régional du Cancer 5 Millegen SA, Labège, F-31670, 6 Biochemistry Laboratory, Instituto Dermopatico Dell'Immacolata, Department of Experimental...
// Pauline Estupina 1, 2, 3, 4 , Alexandre Fontayne 5 Jean-Marc Barret 6 Nathalie Kersual Olivier Dubreuil Marion Le Blay Pichard Marta Jarlier Martine Pugnière Maëva Chauvin Thierry Chardès Jean-Pierre Pouget Emmanuel Deshayes Alexis Rossignol 7 Toufik Abache Christophe de Romeuf Aurélie Terrier Lucie Verhaeghe Christine Gaucher Jean-François Prost André Pèlegrin 4, * Isabelle Navarro-Teulon 1 IRCM, Institut Recherche en Cancérologie Montpellier, F-34298, France 2 INSERM, U896, 3 Université...